<DOC>
	<DOCNO>NCT00488618</DOCNO>
	<brief_summary>This study design evaluate efficacy , safety , tolerability RGH-188 monotherapy treatment acute mania . This study 5 week duration ; 3 week double-blind treatment 2-weeks safety follow-up . All patient meet eligibility criterion randomize one two treatment group : RGH-188 placebo</brief_summary>
	<brief_title>Study Evaluating RGH-188 Treatment Patients With Acute Mania</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Male female inpatient 18 65 year age Meeting DSMIV criterion bipolar I disorder , acute manic mixed episode Having total Young Mania Rating Scale ( YMRS ) score &gt; = 20 score least 4 two follow YMRS item : Irritability , Speech , Content , Disruptive/Aggressive Behavior Patients exhibit abnormality physical examination , abnormal vitalsigns , ECG , clinical laboratory value ( TSH ) . Patients MADRS total score &gt; = 18 Visit 2 . Patients experience first manic episode . Patients receive electroconvulsive therapy ( ECT ) depot neuroleptic 3 month prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Mania</keyword>
	<keyword>Bipolar I Disorder</keyword>
	<keyword>Acute Mania Associated Bipolar I Disorder</keyword>
</DOC>